HIV Integrase Inhibitors

Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor

Organic Cation Transporter 2 Inhibitors

Multidrug and Toxin Extrusion Transporter 1 Inhibitors

Nucleoside Reverse Transcriptase Inhibitors

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Cytochrome P450 1A1 Inhibitors

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Acquired Immunodeficiency Syndrome

HIV Infections

<section class="Section" data-sectioncode="34089-3"><a name="ID_ee09854e-f417-49a1-9ff6-a01dc162be87"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>TRIUMEQ and TRIUMEQ PDTRIUMEQ and TRIUMEQ PD contain an INSTI (dolutegravir) and 2 nucleoside analogues (abacavir and lamivudine) with inhibitory activity against HIV.Each film-coated tablet of TRIUMEQ, for oral use, contains 600 mg of abacavir (present as 702 mg of abacavir sulfate), 50 mg of dolutegravir (present as 52.6 mg of dolutegravir sodium), and 300 mg of lamivudine. The inactive ingredients of TRIUMEQ tablets include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate. The tablet film‑coating contains the inactive ingredients iron oxide black, iron oxide red, macrogol/PEG, polyvinyl alcohol–part hydrolyzed, talc, and titanium oxide.Each film-coated tablet of TRIUMEQ PD for oral suspension contains 60 mg of abacavir (present as 70.2 mg of abacavir sulfate), 5 mg of dolutegravir (present as 5.26 mg of dolutegravir sodium), and 30 mg of lamivudine. The inactive ingredients of TRIUMEQ PD tablets include acesulfame potassium, crospovidone, mannitol, microcrystalline cellulose, povidone K29/32, silicified microcrystalline cellulose, sodium starch glycolate, sodium stearyl fumarate, strawberry cream flavor and sucralose. The tablet film-coating contains the inactive ingredients: ferric oxide yellow, macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc and titanium dioxide.Abacavir SulfateThe chemical name of abacavir sulfate is (1S,cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol sulfate (salt) (2:1). It has a molecular formula of (C14H18N6O)2•H2SO4 and a molecular weight of 670.76 g/mol. It has the following structural formula:<div class="Figure"><a name="id2743521"></a><img alt="Abacavir sulfate chemical structure" src="triumeq-spl-graphic-01.jpg"/></div>Abacavir sulfate is a white to off-white solid and is soluble in water.Dolutegravir SodiumThe chemical name of dolutegravir sodium is sodium (4R,12aS)-9-{[(2,4-difluorophenyl)methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate. The empirical formula is C20H18F2N3NaO5 and the molecular weight is 441.36 g/mol. It has the following structural formula:<div class="Figure"><a name="id-103428125"></a><img alt="Dolutegravir sodium chemical structure" src="triumeq-spl-graphic-02.jpg"/></div>Dolutegravir sodium is a white to light yellow powder and is slightly soluble in water.LamivudineThe chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. Lamivudine is the (‑)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (‑)2′,3′-dideoxy, 3′-thiacytidine. It has a molecular formula of C8H11N3O3S and a molecular weight of 229.3 g/mol. It has the following structural formula:<div class="Figure"><a name="id2743567"></a><img alt="Lamivudine chemical structure" src="triumeq-spl-graphic-03.jpg"/></div>Lamivudine is a white to off-white crystalline solid and is soluble in water.</section>

Triumeq

dolutegravir

abacavir / dolutegravir / lamivudine

abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet

abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet [Triumeq]

abacavir

abacavir 60 MG / dolutegravir 5 MG / lamivudine 30 MG Tablet for Oral Suspension

abacavir 60 MG / dolutegravir 5 MG / lamivudine 30 MG Tablet for Oral Suspension [Triumeq]

lamivudine

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Reimbursement Information

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity 

ViiVConnect Enrollment Form 

ViiVConnect Online Portal - HCP Office 

Enroll in Patient Savings Program 

Common Patient Assistance Program Application (CPAPA)

Instructions For Use [Tablets for Oral Suspension]: HIV 